Alternatives to Cellares

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing first-in-class oral therapy for BK polyomavirus infections.

Developing novel male contraceptives.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Advancing targeted alpha therapies.

A biopharmaceutical company focused on drug discovery and development.

Platform designed to cut cell and gene therapy production costs.

Develops and distributes bioreactor technology for stem cell cultivation.

AI-enabled technology for cell biology research and biopharma development.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Accelerating medicine for the people who need it, prescribe it, and create it.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Clinical-stage biotech company developing transformative cytokine therapies.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Global supplier of life science research tools, including antibodies, reagents, and assays.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.